electroCore’s gammaCore Wins Reimbursement Approval in Belgium

gammaCore Sapphire (nVNS) from electroCore Inc. has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV/INAMI) in Belgium.

The policy now provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy’s efficacy and cost-effectiveness and ensures broader access for Belgian patients.

“The reimbursement of gammaCore by RIZIV/INAMI is a step forward for patients suffering from cluster headaches in Belgium,” said Prof. Paemeleire, leading the Headache Clinic of the Neurology Department at Ghent University Hospital. “This decision reflects the growing recognition of the clinical and economic benefits of non-invasive vagus nerve stimulation. As a healthcare provider, I am pleased that this reimbursement will now allow more patients to access a therapy that can significantly improve their daily lives while contributing to a more sustainable healthcare system.”

The reimbursement policy inclusion was made possible through Silvert Medical, electroCore’s distribution partner in Belgium. Silvert Medical leveraged its local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries.

“Securing long-term reimbursement in Belgium, in the center of Europe, is a major milestone in expanding access to our non-invasive therapies,” said Tanja Martin, senior director of Strategic Product Lifecycle at electroCore. “We’re proud to partner with Silvert Medical to bring gammaCore to patients in Belgium.”

electroCore Inc. is a commercial stage bioelectronic technology company developing non-invasive bioelectronic technologies. The company’s two prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products using bioelectronic technologies to promote general wellness and human performance.